Clearside Biomedical, Inc. — Director's Dealing 2019

Nov 26, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Clearside Biomedical, Inc. (CLSD)
CIK: 0001539029
Period of Report: 2019-11-22

Reporting Person: Thorp Clay (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-11-22	Common Stock	A	1518026	$1.054	Acquired	4984420	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8000	Direct

Footnotes

F1: The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of Hatteras Venture Partners III, LP ("HVP III") and Hatteras Venture Affiliates III, LP ("HVA III"); (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC"); and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP ("HVP IV") and Hatteras NC Fund, LP ("Hatteras NC"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.

F2: The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.